Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes
Decision brief
Answer first · skim in under a minute
Nektar Therapeutics’ pipeline remains centered on REZPEG, with active Phase 2 programs in atopic dermatitis and alopecia areata and a completed SLE study. The company also has an amphotericin B-linked program context and recent business changes that matter for BD teams and investors.
This Nektar therapeutics pipeline update puts REZPEG first. Phase 2b REZOLVE-AD maintenance data and AAD 2026 presentations support a Phase 3 atopic dermatitis start, while legacy amphotericin B and old UK site history are background—not 2026 value drivers.
Contents10 sections
Key Takeaways
- Lead asset: rezpegaldesleukin (REZPEG / NKTR-358), a Treg stimulator.
- REZOLVE-AD (NCT06136741) enrolled 393 patients; Feb. 10, 2026 maintenance data favored Q4W and Q12W dosing.
- Phase 3 ZENITH-AD (NCT07690371) is recruiting for ages ≥12 with moderate-to-severe atopic dermatitis.
- Inhaled amphotericin orphan EU/3/06/391 was withdrawn in 2019; do not treat it as an active catalyst.
What is driving the Nektar therapeutics pipeline now?
Nektar is a clinical-stage immunology company. The live story is REZPEG in atopic dermatitis and alopecia areata, not PEGylation manufacturing or abandoned antifungal programs.
Company materials describe REZPEG as a first-in-class regulatory T-cell stimulator. That mechanism sits upstream of several inflammatory pathways used in dermatology BD models.
How strong are the REZOLVE-AD data?
On Feb. 10, 2026, Nektar reported positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study. The Phase 2b trial enrolled 393 patients with moderate-to-severe atopic dermatitis.
Patients who reached EASI-50 after induction were re-randomized to monthly (Q4W) or quarterly (Q12W) maintenance through week 52. Nektar said both schedules sustained disease control and deepened some responses, including EASI-100 conversions.
Source: PR Newswire — REZOLVE-AD maintenance data.
Which trials define the next catalysts?
- NCT06136741 — REZOLVE-AD Phase 2b; active, not recruiting
- NCT06340360 — REZOLVE-AA Phase 2b; active, not recruiting
- NCT07690371 — ZENITH AD-1 Phase 3; recruiting
Nektar’s Q1 2026 results wire said the company planned to initiate ZENITH-AD by July 2026 and hold an End-of-Phase 2 FDA meeting on alopecia areata in Q2 2026.
Source: PR Newswire — Nektar Q1 2026 results.
Where do amphotericin B and UK site changes fit?
Older headlines sometimes mix REZPEG with Nektar’s past inhaled amphotericin B work and UK operations. Those are historical.
EMA lists orphan designation EU/3/06/391 for amphotericin B for inhalation, originally granted to Nektar Therapeutics UK Ltd in 2006. The designation was withdrawn from the Community Register in February 2019 at the sponsor’s request.
EMA record: EMA orphan designation EU/3/06/391.
That history explains archive search noise. It does not change the 2026 REZPEG catalyst path.
Operating focus after manufacturing exits
Nektar has been simplifying around immunology R&D. Recent results commentary ties lower product sales to the December 2024 sale of the Huntsville manufacturing facility. Teams should model Nektar as a clinical-stage REZPEG story, not a PEGylation plant owner.
What remains unproven
Phase 2b maintenance gains do not prove Phase 3 success. Fast Track designations, when cited by the company, are not approvals. Alopecia areata Phase 3 design is not final until FDA meeting minutes and protocols lock.
Related NovaPharma coverage
- Nektar REZPEG clinical programs analysis
- Cardiff Oncology pipeline update
- Sanofi pipeline pdf update
Frequently Asked Questions
What leads the Nektar therapeutics pipeline in 2026?
Rezpegaldesleukin (REZPEG, NKTR-358), a regulatory T-cell stimulator, leads the pipeline through Phase 2b REZOLVE-AD and REZOLVE-AA programs, with Phase 3 ZENITH-AD (NCT07690371) listed as recruiting.
Is inhaled amphotericin B still an active Nektar catalyst?
No. EMA orphan designation EU/3/06/391 for inhaled amphotericin B linked to Nektar UK was withdrawn in February 2019 at the sponsor’s request. It is not a current late-stage Nektar catalyst.
Which REZPEG trials should teams watch next?
Watch NCT06136741 (REZOLVE-AD), NCT06340360 (REZOLVE-AA), and Phase 3 NCT07690371 (ZENITH AD-1). Nektar’s Q1 2026 update also cited ZENITH-AD initiation timing and an alopecia areata End-of-Phase 2 FDA meeting.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for REZPEG.
Unlock full calendar →Nektar Therapeutics UK Limited pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
